Circulating microRNAs in Hepatocellular Carcinoma: Potential Diagnostic and Prognostic Biomarkers

Author(s): Hamid Reza Mirzaei, Amirhossein Sahebkar, Mohsen Mohammadi, Reza Yari, Hossein Salehi, Mohammad Hasan Jafari, Afshin Namdar, Ehsan Khabazian, Mahmoud Reza Jaafari, Hamed Mirzaei.

Journal Name: Current Pharmaceutical Design

Volume 22 , Issue 34 , 2016

Submit Manuscript
Submit Proposal

Abstract:

Hepatocellular carcinoma (HCC) is one of the most common types of malignancies worldwide. There is little information on the mechanisms involved in the pathogenesis of this disease. Diagnosis of HCC at early stages would be crucial for increasing the survival of patients. Circulating miRNAs have emerged as one of the most attractive tools for an early diagnosis of cancers. Various studies have shown that there is an aberrant expression of miRNAs such as miR-25, miR-375, miR-206, miR-223, miR- 92a, miR-222, miR-1, let- 7f and miR-21 in HCC. Circulating and tissue miRNAs have also key roles in the pathogenesis of HCC by affecting several biologically important pathways such as p53, p21, PTEN, PI3K-AKT, c-Myc and STAT3. In this review, we summarize the current knowledge on the role of miRNAs in diagnosis, prognosis, and treatment of HCC.

Keywords: Hepatocellular carcinoma, MicroRNA, diagnosis, prognosis, cancer.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 22
ISSUE: 34
Year: 2016
Page: [5257 - 5269]
Pages: 13
DOI: 10.2174/1381612822666160303110838
Price: $58

Article Metrics

PDF: 37
HTML: 3
EPUB: 1
PRC: 1